ReviewCurrent State of Neoadjuvant Radiotherapy for Rectal Cancer
Introduction
In 2020, colorectal cancer is the third most commonly diagnosed cancer but is the second leading cause of cancer-related deaths.1 Colorectal cancer is considered a disease of the developed world, with up to 9x incidence rates in developed countries such as Australia and Northern America, compared to developing countries. Rectal cancer accounts for approximately 30% of colorectal cancer diagnoses. In the early 2000s, the standard of care for management of locally advanced rectal cancer is neoadjuvant radiotherapy (with/ without chemotherapy) followed by surgery and adjuvant chemotherapy. The introduction of neoadjuvant radiotherapy and total mesorectal excision (TME) surgery has reduced the 5-year local recurrence rates to 10% or less.2, 3, 4, 5 The risk of developing distant metastatic disease, however, remained high at 30% in those with locally advance disease.2,3,5,6 In the past decade, to improve patients’ survival, patients’ quality of life, treatment compliance and cost-effectiveness, novel treatment regimens were designed and trialed. In parallel of the developments of these new treatment options, there is a recognized need and advancements in the field of biomarkers to aid treatment personalization to patient's tumor biology.
Section snippets
Preoperative Versus Postoperative (Chemo)radiotherapy
Postoperative chemoradiotherapy was established as the standard of care for locally advanced rectal cancer in the 1990s following the GITSG 7175,7 NCCTG 7947518 and the NSABP R-019 trials demonstrating improved survival and locoregional control with adjuvant chemoradiotherapy.
With treatment-related side-effects of up to 61% in adjuvant trials, the sequencing of radiotherapy in relation to surgery was investigated in the 1990s. The proposed potential benefits of preoperative chemoradiotherapy
Short Versus Long Course Radiotherapy
The Swedish Rectal Cancer Trial utilized short course preoperative radiotherapy in their trial design randomizing patients to 25Gy in 5 fractions radiotherapy followed by early surgery or surgery alone. The preoperative arm had significantly lower local recurrence rates (12% vs. 27%, P< .001) and better 5-year overall survival (38% vs. 30%, P= .008). As the study was conducted in the pre-TME surgery era, one of the main criticisms was that patients did not undergo adequate surgery, thereby
Total Neoadjuvant Therapy (TNT)
Despite the use of adjuvant chemotherapy, distant disease now accounts for approximately 30% of recurrences in patients with locally advanced rectal (T3/T4) cancer.3,5,24 Decline in patient performance status following rectal surgery compromises the intended intensity of adjuvant chemotherapy. Treatment compliance is higher in the preoperative setting when patients are fitter and more likely to complete the intended treatment. In addition, with a shift in the treatment paradigm towards delayed
Nonoperative Approach After Chemoradiotherapy
As up to 30% of patients who receive preoperative chemoradiotherapy reportedly achieve pathological complete response,33, 34, 35, 36 it was proposed that this subgroup of patients may be spared surgery. Habr-Gama et al37 first described the long-term results of an observational study where patients who had complete clinical response after chemoradiotherapy were spared surgery. The nonoperative management surveillance approach described was stringent and rigorous with monthly follow-up visits
Omission of Neoadjuvant Radiotherapy
More recently, there has been interest to explore strategies that allow for omission of neoadjuvant radiotherapy given the potential impact of late effects on patient long-term quality of life.
An early single institution phase II study examined the potential use of neoadjuvant FOLFOX (6 cycles) and bevacizumab in 32 patients with stage II-III rectal cancer, with responders to proceed to surgery without radiotherapy and nonresponders to have radiotherapy before surgery.44 Of the 30 patients who
Imaging and Blood Biomarkers for Omission of RT or Surgery
With some recent studies indicating the potential for omission of radiotherapy or surgery in some patients, there is a need for the development of methods for identification of treatment responders to allow for optimal patient selection for these treatment strategies. Imaging, blood and tissue biomarkers have been investigated and require further validation or development of consensus guidelines for use in the clinical setting.
MRI is an established imaging modality for staging in rectal cancer
Conclusions
The management of locally advanced rectal cancer remained an evolving landscape. Clinicians and patients now have multiple treatment options to consider: short versus long course radiotherapy, total neoadjuvant therapy, nonoperative approach, and omission of radiotherapy. With the multitude of acceptable and reasonable treatment options, we are now in need of a strategy to “match patient to the right treatment,” optimizing the therapeutic effect of each treatment modality whilst limiting
Declaration of Competing Interest
None.
References (99)
- et al.
Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial
Lancet
(2009) - et al.
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study
Lancet Oncol
(2014) - et al.
Adjuvant postoperative radiotherapy and chemotherapy in rectal carcinoma: a review of the Gastrointestinal Tumor Study Group experience
Radiother Oncol
(1988) - et al.
Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial
Lancet Oncol
(2011) - et al.
Quality of life, anorectal and sexual functions after preoperative radiotherapy for rectal cancer: report of a randomised trial
Radiother Oncol
(2007) - et al.
The impact on health-related quality of life in the first 12 months: a randomised comparison of preoperative short-course radiation versus long-course chemoradiation for T3 rectal cancer (Trans-Tasman Radiation Oncology Group Trial 01.04)
Eur J Cancer
(2016) - et al.
Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial
Lancet Oncol
(2017) - et al.
Tumour regression after radiotherapy for rectal cancer - results from the randomised Stockholm III trial
Radiother Oncol
(2019) - et al.
Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Ann Oncol
(2017) - et al.
Anal sphincter conservation for patients with adenocarcinoma of the distal rectum: long-term results of radiation therapy oncology group protocol 89-02
Int J Radiat Oncol Biol Phys
(2000)